Company Filing History:
2 out of 37 
2 out of 1,345 
Years Active: 2020-2022
Title: Daniel A Schwemmer Gipe: Innovator in Hypercholesterolemia Treatment
Introduction
Daniel A Schwemmer Gipe is an accomplished inventor based in Tarrytown, NY, USA. He has made significant contributions to the field of medicine, particularly in the treatment of heterozygous familial hypercholesterolemia (heFH). With a total of two patents to his name, Gipe continues to push the boundaries of innovation in the healthcare sector.
Latest Patents
Gipe's latest patents focus on methods for treating patients with heterozygous familial hypercholesterolemia using an anti-PCSK9 antibody. These patents provide a groundbreaking approach to managing hypercholesterolemia by administering pharmaceutical compositions that include a PCSK9 inhibitor. The exemplary antibody referred to in these patents is known as mAb316P. The methods are particularly beneficial for patients who do not achieve adequate control through maximum tolerated dose statin therapy, whether used alone or in conjunction with other lipid-lowering therapies.
Career Highlights
Throughout his career, Daniel A Schwemmer Gipe has been associated with reputable companies such as Sanofi Biotechnology and Regeneron Pharmaceuticals, Inc. His involvement in these organizations has allowed him to collaborate on significant medical advancements, particularly in cholesterol management and antibody therapy.
Collaborations
Gipe has collaborated with numerous professionals in the field, including Marie Baccara-Dinet and Corinne Hanotin. These partnerships have enriched his work and contributed to the development of effective treatments for complex medical conditions.
Conclusion
Daniel A Schwemmer Gipe exemplifies the innovative spirit of modern healthcare inventors. His work on treatments for heterozygous familial hypercholesterolemia stands as a testament to the potential breakthroughs that arise from dedicated research and collaboration. With his continued focus on improving patient care, Gipe plays a crucial role in the future of cardiovascular health.